Compare Recursion Pharmaceuticals Inc (RXRX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Consumer Staples Select Sector SPDR Fund trades at $83.22 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 6.3× Recursion Pharmaceuticals Inc's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| RXRX | XLP | |
|---|---|---|
Market Cap | $2.14B | $13.50B |
Volume | 30,789,535 | 14,599,953 |
Sector | Health | — |
52-Week High | $6.79 | $90.00 |
52-Week Low | $2.84 | $75.61 |
Typical Hold Time | 22 Days | 72 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
XLP trades at $81.70, showing slight weakness with a 0.09% decline amid bearish technical signals. The ETF maintains strong analyst support with a 100% buy rating from 2 analysts, though technical indicators show moving averages and overall signals are bearish. Recent news highlights XLP's defensive characteristics and competitive expense ratio advantage over peers.
The consumer staples ETF offers defensive exposure during market volatility, supported by positive sector performance in 2026. Key risks include interest rate sensitivity and potential consumer spending slowdowns. Analyst consensus remains bullish despite technical headwinds, positioning XLP as a core defensive holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
